Cargando…
Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes
The progressive nature of type 2 diabetes (T2D) means that many patients will require basal insulin therapy at some point in the course of the disease due to β-cell failure. As basal insulin primarily targets fasting plasma glucose, patients may still experience considerable postprandial glucose exc...
Autores principales: | Perreault, Leigh, Rodbard, Helena, Valentine, Virginia, Johnson, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824345/ https://www.ncbi.nlm.nih.gov/pubmed/30610613 http://dx.doi.org/10.1007/s12325-018-0868-9 |
Ejemplares similares
-
Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes
por: Valentine, Virginia, et al.
Publicado: (2017) -
Fixed combination of repaglinide and metformin in the management of type 2 diabetes
por: Moses, Robert
Publicado: (2009) -
Fixed-Ratio Combinations
por: Tran, Emmeline
Publicado: (2017) -
Fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination
por: Fleming, Joshua W, et al.
Publicado: (2015) -
Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
por: Reynolds, Jonathan K
Publicado: (2009)